Nomelcitinib

Overview

Nomelcitinib is a TYK2 inhibitor that modulates the IL23 signaling pathway. Nomelcitinib is used for research on multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, systemic lupus erythematosus, psoriasis, psoriatic arthritis, Crohn's disease, Sjögren's syndrome, and scleroderma.

Application

Products | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Musculoskeletal and Skin Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Autoimmune Disease | Products > Disease Areas > Neurodegenerative Disease | Products > Disease Areas > Skin Inflammation | Products > Disease Areas > Arthritis | Products > Disease Areas > Digestive System Inflammation | Products > Disease Areas > Systemic Lupus Erythematosus | Products > Disease Areas > Multiple Sclerosis | Products > Disease Areas > Crohn's Disease | Products > Disease Areas > Psoriasis | Products > Disease Areas > Rheumatoid Arthritis | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > Stem Cell/Wnt | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > JAK/STAT Signaling | Products > Signaling Pathways > Immunology/Inflammation | Products > Research Areas > Neurological Disease | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > JAK | Products > Signaling Pathways > Interleukin Related

Product Information

• Catalog No.: HY-184075S
• CAS No.: 2794195-73-4
• Molecular Formula: C16H14D3ClN6O4S
• Molecular Weight: 427.88
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source